January 13, 2020 / 1:10 PM / 14 days ago

BRIEF-Adaptive, Genentech Partner To Use Clonoseq Assay In Study Of Chronic Lymphocytic Leukemia Patients

Jan 13 (Reuters) - Adaptive Biotechnologies Corp:

* ADAPTIVE AND GENENTECH PARTNER TO USE CLONOSEQ ASSAY TO MEASURE MINIMAL RESIDUAL DISEASE AS A PRIMARY ENDPOINT IN PHASE III STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

* ADAPTIVE BIOTECHNOLOGIES - WILL RECEIVE UPFRONT, SAMPLE TESTING PAYMENTS TO ADVANCE DEVELOPMENT & POTENTIAL EXPEDITED APPROVAL OF VENETOCLAX Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below